Segments Covered in the Global Companion Diagnostics Market Report:
The global companion diagnostics market is segmented based on product type, technology, disease indication, and region as follows:
- Product Type (Revenue, USD Billion; 2022–2030)
- Diagnostics Kits
- Assays
- Others
- Technology (Revenue, USD Billion; 2022–2030)
- PCR
- NGS
- ISH
- IHC
- Disease Indication (Revenue, USD Billion; 2022–2030)
- Breast Cancer
- Lung Cancer
- Blood Cancer
- Colorectal Cancer
- Others
- Region (Revenue, USD Billion; 2022–2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- ASEAN
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
- North America
Frequently Asked Questions
The current market size of the Companion Diagnostics industry is approximately $5.6 billion.
Factors such as increasing demand for personalized medicine and rising prevalence of chronic diseases are contributing significantly to the growth of the Companion Diagnostics market.
Regulatory challenges and high development costs are key factors hampering the growth of the Companion Diagnostics Market.
The leading component segment in the Companion Diagnostics Market is the Assay Kits segment.
Major players operating in the Companion Diagnostics Market include Roche Diagnostics, Qiagen N.V., and Abbott Laboratories.
The CAGR of the Companion Diagnostics Market is projected to be around 12.3%, with a market size expected to reach $11.3 billion by 2030.